SG11202103801UA - Method for the treatment of myasthenia gravis - Google Patents

Method for the treatment of myasthenia gravis

Info

Publication number
SG11202103801UA
SG11202103801UA SG11202103801UA SG11202103801UA SG11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA SG 11202103801U A SG11202103801U A SG 11202103801UA
Authority
SG
Singapore
Prior art keywords
treatment
myasthenia gravis
gravis
myasthenia
Prior art date
Application number
SG11202103801UA
Other languages
English (en)
Inventor
Melissa Kaye Brock
William James Byrnes
Bernhard Heinrich Greve
Claus Peter Kiessling
Grant Langdon
Manis Elizabeth Webster
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of SG11202103801UA publication Critical patent/SG11202103801UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202103801UA 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis SG11202103801UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746174P 2018-10-16 2018-10-16
PCT/EP2019/078093 WO2020079086A1 (fr) 2018-10-16 2019-10-16 Méthode de traitement de la myasthénie grave

Publications (1)

Publication Number Publication Date
SG11202103801UA true SG11202103801UA (en) 2021-05-28

Family

ID=68290236

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103801UA SG11202103801UA (en) 2018-10-16 2019-10-16 Method for the treatment of myasthenia gravis

Country Status (14)

Country Link
US (1) US20220144941A1 (fr)
EP (1) EP3866933A1 (fr)
JP (1) JP7518821B2 (fr)
KR (1) KR20210078517A (fr)
CN (1) CN113646051A (fr)
AR (1) AR117653A1 (fr)
AU (1) AU2019361247A1 (fr)
BR (1) BR112021007092A2 (fr)
CA (1) CA3116091A1 (fr)
IL (1) IL282137A (fr)
MA (1) MA53903A (fr)
MX (1) MX2021004351A (fr)
SG (1) SG11202103801UA (fr)
WO (1) WO2020079086A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111712259A (zh) 2017-12-13 2020-09-25 动量制药公司 Fcrn抗体及其使用方法
MX2023005313A (es) * 2020-11-06 2023-07-11 Momenta Pharmaceuticals Inc Anticuerpos fcrn y metodos de uso de estos.
WO2023198806A1 (fr) 2022-04-13 2023-10-19 Ose Immunotherapeutics Nouvelle classe de molécules pour la clairance sélective d'anticorps
WO2023215587A1 (fr) * 2022-05-05 2023-11-09 UCB Biopharma SRL Traitement de la myasthénie grave avec du zilucoplan
TW202409086A (zh) * 2022-06-11 2024-03-01 美商英伊布里克斯公司 FcRn-結合多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0542810A1 (fr) 1990-08-02 1993-05-26 B.R. Centre Limited Procedes de production de proteines presentant une fonction souhaitee
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
WO2004051268A1 (fr) 2002-12-03 2004-06-17 Celltech R & D Limited Dosage biologique permettant d'identifier des cellules productrices d'anticorps
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014655A2 (fr) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugues d'amidon d'hydroxyalkyle et de proteine
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20100266530A1 (en) 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
EP2520588A1 (fr) 2005-08-19 2012-11-07 Abbott Laboratories Immunoglobuline à double domaine variable et ses utilisations
EP1986690A4 (fr) 2006-01-25 2009-05-13 Univ New York State Res Found ANTICORPS ANTI-FcRn UTILISES DANS LE TRAITEMENT D'ETATS AUTO/ALLO-IMMUNS
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2535349A1 (fr) 2007-09-26 2012-12-19 UCB Pharma S.A. Fusions d'anticorps à double spécificité
KR20190104432A (ko) 2008-04-25 2019-09-09 다이액스 코포레이션 Ｆｃｒｎ에 대한 항체 및 이들의 용도
CA2737241C (fr) 2008-09-26 2017-08-29 Ucb Pharma S.A. Proteines de fusion d'anticorps multivalentes
CN104367299B (zh) 2009-07-14 2017-09-15 波技术视觉***公司 眼科手术测量***
WO2011030107A1 (fr) 2009-09-10 2011-03-17 Ucb Pharma S.A. Anticorps multivalents
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201320066D0 (en) 2013-11-13 2013-12-25 Ucb Pharma Sa Biological products
MX2016014210A (es) 2014-04-30 2017-05-01 Hanall Biopharma Co Ltd Anticuerpo que se une a fcrn para tratar enfermedades autoinmunes.
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
HRP20231399T1 (hr) 2015-01-30 2024-02-16 Momenta Pharmaceuticals, Inc. Fcrn antitijela i načini njihove uporabe
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies

Also Published As

Publication number Publication date
KR20210078517A (ko) 2021-06-28
EP3866933A1 (fr) 2021-08-25
IL282137A (en) 2021-05-31
CA3116091A1 (fr) 2020-04-23
MA53903A (fr) 2021-08-25
JP7518821B2 (ja) 2024-07-18
BR112021007092A2 (pt) 2021-08-03
AR117653A1 (es) 2021-08-25
CN113646051A (zh) 2021-11-12
MX2021004351A (es) 2021-05-31
AU2019361247A1 (en) 2021-05-27
US20220144941A1 (en) 2022-05-12
JP2022512713A (ja) 2022-02-07
WO2020079086A1 (fr) 2020-04-23

Similar Documents

Publication Publication Date Title
IL274603A (en) Use of FCRN antagonists to treat myasthenia gravis
IL276917A (en) A process for the preparation of alubixivet
IL282137A (en) A method for treating severe muscle weakness
EP3426748A4 (fr) Procédé d'augmentation de la masse volumique d'une saumure de traitement de puits
EP3463461A4 (fr) Procédés de traitement de la myasthénie grave généralisée réfractaire
IL283948A (en) Methods for treating depression
GB202106894D0 (en) Process for the preparation of 3alpha-hydroxy-5#LPHA-Pregnan-20-one (brexanolone)
EP3894768C0 (fr) Procédés de cryo-durcisssement
GB201804594D0 (en) Bonegraft substituteand method of manufacture
RS64534B1 (sr) Postupak za pripremu n-alkil-nitratoetil nitramina
IL281792A (en) Treatment methods
GB201802839D0 (en) Method of manufacture
IL281254A (en) A process for the preparation of lanbatinib
IL281839A (en) Treatment methods
ZA202001536B (en) Method for the treatment of wastewaters
GB201815478D0 (en) Subsea apparatus
IL281727A (en) Device to create target
SG11202105877YA (en) Method of treatment
EP3877361C0 (fr) Procédé de préparation d'arylsulfonylpropènenitriles
PL3599256T3 (pl) Sposób wytwarzania poliorganosiloksanów
GB201917487D0 (en) Methods for the treatment of retinoblastoma
HK1254604A1 (zh) 提高ubiad1表達的方法
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
IL278861A (en) A method for the production of halogenated N-arylpyrazoles